Edip Gayrimenkul Yatirim Sanayi ve Ticaret A.S. (IST:EDIP)
Turkey · Delayed Price · Currency is TRY 37.24
-0.46 (-1.22%)
Last updated: Aug 13, 2025
CTI BioPharma Income Statement
Financials in millions TRY. Fiscal year is January - December.
Millions TRY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Rental Revenue | 580.41 | 561.01 | 550.05 | 327.02 | 73.23 | 58.48 | Upgrade |
| 580.41 | 561.01 | 550.05 | 327.02 | 73.23 | 58.48 | Upgrade | |
Revenue Growth (YoY | -1.44% | 1.99% | 68.20% | 346.59% | 25.22% | -17.64% | Upgrade |
Property Expenses | 258.17 | 255.26 | 241.18 | 166.33 | 36.15 | 29 | Upgrade |
Selling, General & Administrative | 32.06 | 30.84 | 19.25 | 9.94 | 3.99 | 3.31 | Upgrade |
Other Operating Expenses | 27.04 | 23.22 | 13.5 | 13.45 | 3.05 | 4.69 | Upgrade |
Total Operating Expenses | 317.27 | 309.32 | 273.93 | 189.72 | 43.19 | 37 | Upgrade |
Operating Income | 263.14 | 251.69 | 276.13 | 137.3 | 30.04 | 21.47 | Upgrade |
Interest Expense | -284.67 | -287.11 | -188.93 | -287.87 | -36.53 | -43.12 | Upgrade |
Interest & Investment Income | 9.95 | 16.74 | 69.09 | 29.55 | 0.25 | 0.05 | Upgrade |
Currency Exchange Gain (Loss) | 15.04 | 15.05 | 0.84 | -403.08 | -414.68 | -174.55 | Upgrade |
Other Non-Operating Income | 525.12 | 577.06 | 1,387 | 1,160 | -0.11 | -0.12 | Upgrade |
EBT Excluding Unusual Items | 528.59 | 573.44 | 1,544 | 635.88 | -421.02 | -196.27 | Upgrade |
Gain (Loss) on Sale of Investments | -1.39 | - | - | - | -7.1 | -0.01 | Upgrade |
Asset Writedown | 73.12 | 73.12 | 528.6 | 687.56 | 218.52 | -38.79 | Upgrade |
Total Legal Settlements | -0.51 | -0.81 | -0.73 | -0.21 | -0.06 | -0.05 | Upgrade |
Pretax Income | 599.81 | 645.76 | 2,072 | 1,323 | -209.67 | -235.12 | Upgrade |
Income Tax Expense | -259.73 | -288.62 | -616.73 | 281.48 | -28.52 | -33.32 | Upgrade |
Earnings From Continuing Operations | 859.54 | 934.38 | 2,688 | 1,042 | -181.15 | -201.8 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 0 | 0 | Upgrade |
Net Income | 859.54 | 934.38 | 2,688 | 1,042 | -181.15 | -201.8 | Upgrade |
Net Income to Common | 859.54 | 934.38 | 2,688 | 1,042 | -181.15 | -201.8 | Upgrade |
Net Income Growth | -67.44% | -65.24% | 158.05% | - | - | - | Upgrade |
Basic Shares Outstanding | 65 | 65 | 65 | 65 | 65 | 65 | Upgrade |
Diluted Shares Outstanding | 65 | 65 | 65 | 65 | 65 | 65 | Upgrade |
EPS (Basic) | 13.22 | 14.38 | 41.36 | 16.03 | -2.79 | -3.10 | Upgrade |
EPS (Diluted) | 13.22 | 14.38 | 41.36 | 16.03 | -2.79 | -3.10 | Upgrade |
EPS Growth | -67.44% | -65.24% | 158.05% | - | - | - | Upgrade |
Operating Margin | 45.34% | 44.86% | 50.20% | 41.98% | 41.02% | 36.72% | Upgrade |
Profit Margin | 148.09% | 166.55% | 488.73% | 318.56% | -247.39% | -345.09% | Upgrade |
EBITDA | 269.72 | 258.01 | 278.36 | 138.99 | 30.3 | 21.73 | Upgrade |
EBITDA Margin | 46.47% | 45.99% | 50.61% | 42.50% | 41.37% | 37.16% | Upgrade |
D&A For Ebitda | 6.58 | 6.32 | 2.23 | 1.69 | 0.26 | 0.25 | Upgrade |
EBIT | 263.14 | 251.69 | 276.13 | 137.3 | 30.04 | 21.47 | Upgrade |
EBIT Margin | 45.34% | 44.86% | 50.20% | 41.98% | 41.02% | 36.72% | Upgrade |
Effective Tax Rate | - | - | - | 21.27% | - | - | Upgrade |
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.